FDA Approves Three Diabetes Drugs

Monday, 28 Jan 2013 11:57 AM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
Three new drugs to treat Type 2 diabetes have been approved by the U.S. Food and Drug Administration.

All three drugs contain a new active ingredient, alogliptin, either alone or in combination with other, previously approved medications. The newly approved drugs include Nesina (alogliptin), Kazano (alogliptin plus metformin) and Oseni (alogliptin plus pioglitazone), the FDA said in a news release.

"Controlling blood sugar levels is very important in the overall treatment and care of diabetes," Dr. Mary Parks, director of the Division of Metabolism and Endocrinology Products in the FDA's Center for Drug Evaluation and Research, said in the statement. "Alogliptin helps stimulate the release of insulin after a meal, which leads to better blood sugar control."

More than 24 million people in the United States are currently affected by Type 2 diabetes, which is closely linked with obesity. In the Type 2 form of the disease, people gradually develop resistance to insulin or fail to produce enough of the hormone, resulting in rising blood sugar levels. That can lead to other health problems, such as heart disease, vision problems and neural or kidney dysfunction.

The FDA urges that the new medications be used in combination with a healthy diet and exercise to help bring diabetes under control. All of the drugs underwent study either as stand-alone products or used alongside standard diabetes medications such as sulfonyureas or insulin.

In the case of Nesina, the drug showed safety and effectiveness across 14 clinical trials, involving more than 8,500 patients, according to the FDA. The most common side effects included stuffy or runny nose, headache, and upper respiratory tract infections.

Kazano's safety and effectiveness were tested in four clinical trials involving more than 2,500 patients. Side effects included those seen with Nesina, as well as diarrhea, high blood pressure and back pain, the FDA said. The agency is also requesting that a "boxed warning" be included on Kazano's labeling, highlighting the potential risk of lactic acidosis (lactic acid buildup in the blood), which can occur in products containing metformin.

Oseni was studied in four clinical trials involving more than 1,500 patients, the FDA noted. Side effects were similar to those seen with Nesina, as well as back pain. Oseni's labeling will also carry a boxed warning, this time cautioning users about the risk for heart failure that accompanies drugs containing pioglitazone.

The drugs, which are distributed by Takeda Pharmaceuticals America Inc., will also be subject to what are known as "post-marketing studies," aimed at spotting any emerging risks.
 

© HealthDay

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
You May Also Like

Older People Sleep Less - Now We Know Why

Wednesday, 20 Aug 2014 17:33 PM

A group of brain cells collectively act as a 'sleep switch' that may account for why so many older people have difficult . . .

Mislabeled Fish Could Give You Mercury Poisoning: Study

Wednesday, 20 Aug 2014 17:27 PM

A new study of mislabeled fish sold at retailers in 10 states finds that it can expose consumers to high levels of the h . . .

10 Questions to Ask After Cancer Diagnosis

Wednesday, 20 Aug 2014 17:21 PM

A cancer diagnosis is always difficult. But getting answers to 10 key questions can help patients mobilize their efforts . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved